MT2013-34C: Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia: Standard of Care Considerations

This study facilitates the collection and analysis of outcome data for patients with dyskeratosis congenita (DC) or severe aplastic anemia (SAA) undergoing a hematopoietic stem cell transplant (HSCT). Specific transplant related endpoints include incidence of: -neutrophil engraftment at day 42 and platelet engraftment at 1 year -regimen related morality at 100 days -acute GVHD at 100 days -chronic GVHD at 6 months and 1 year -secondary malignancies